4/9/2014 6:52:07 AM
(Reuters) - India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States after completing a $3.2 billion takeover of its loss-making rival, sources with direct knowledge of the matter said.
Ranbaxy drugs sold in the United States will be gradually rebranded as Sun Pharma treatments as part of a strategy to turn around the company being bought from Japan's Daiichi Sankyo Ltd. The brand is likely to continue to be present in other markets, the sources said.
Help employers find you! Check out all the jobs and post your resume.
comments powered by